On Mar. 8, 2021, AXIM Biotechnologies announced that it had successfully completed point-of-care clinical trials on its much awaited ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies to help understand COVID-19 immunity, validate vaccine’s effectiveness and estimate how long the vaccine will be effective in patients.

The Company conducted two studies, one in partnership with the Company’s manufacturing partner Empowered Diagnostics and the second in partnership with a top accredited university medical center.

The main goal of these studies was to identify the ability of operators to successfully utilize ImmunoPass to accurately measure each participant’s level of neutralizing antibodies. Study findings reveal that operators found ImmunoPass easy to use and that they encountered no issues in using the Company’s test to measure participants’ COVID-19 neutralizing antibodies.

The Company is currently working with Empowered Diagnostics to compile the study results and file an Emergency Use Application (EUA) with the U.S. Food and Drug Administration (FDA) for the use of ImmunoPass in detecting COVID-19 neutralizing antibodies in whole blood at point-of care locations.

AXIM and Empowered Diagnostics are finalizing a robustness study on ImmunoPass to further confirm the test’s accuracy when conducted under varying conditions. To date, the Company has completed various interference studies and live virus studies in this process.